Second primary cutaneous melanoma in patients with advanced melanoma treated with anti‐programmed‐death‐receptor‐1 monoclonal antibodies
| Autor: | Jean-François Emile, M. Hamon, Astrid Blom, L. Chaplain, Elisa Funck-Brentano, O. Kassem, Nicolas Dupin, U. Zimmermann, E. Charvet, T. Sidibé, Selim Aractingi, C. Longvert, Pierre Sohier, A. Gantzer, Philippe Saiag, Nora Kramkimel |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty Skin Neoplasms medicine.drug_class Programmed Cell Death 1 Receptor Population Dermatology Pembrolizumab Monoclonal antibody 030207 dermatology & venereal diseases 03 medical and health sciences Antineoplastic Agents Immunological 0302 clinical medicine Internal medicine medicine Humans Adverse effect education Receptor Melanoma neoplasms education.field_of_study business.industry Antibodies Monoclonal Common Terminology Criteria for Adverse Events Cutaneous melanoma Nivolumab business |
| Zdroj: | British Journal of Dermatology. 184:746-748 |
| ISSN: | 1365-2133 0007-0963 |
| Popis: | Cases of second primary cutaneous melanoma (SPCM), which were mostly BRAF-wild type, have been reported in BRAF-inhibitor-treated advanced cutaneous melanoma patients.1 Anti-programmed-death-receptor-1 (anti-PD-1) monoclonal antibodies (mAb) nivolumab and pembrolizumab have also revolutionized the prognosis of these patients, but 10-15% of them experience grade 3-4 adverse events according to Common Terminology Criteria for Adverse Events The risk of developing a SPCM in this population has not been reported and could be reduced by anti-PD-1 treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text